Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
AZD5004 / Eccogene, AstraZeneca
AZD5004 (ECC5004) Datasheet
Azd5004 – Application in Therapy and Current Clinical Research
Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 ...
Estudio sobre los efectos de AZD5004 en adultos con obesidad o ...
AstraZeneca’s AZD5004 Obesity Trial Edges Forward, Raising New ...
AstraZeneca's Oral GLP-1 Agonist AZD5004 Shows Promise in Phase I ...
AZD5004 (ECC5004) | GLP-1 Receptor Agonist | CAS 2758659-09-3 | Selleck ...
AstraZeneca Presents Promising Early Data on Oral GLP-1 Agonist AZD5004 ...
阿斯利康的AZD5004、罗氏的CT-996与Terns的TERN-601均展现出较好的I期临床数据 - 2025年09月 - - 小牛行研
AstraZeneca’s AZD5004: A Power Move in Obesity Medicine
AstraZeneca: Strong Growth Potential And Market Volatility Offer ...
elecoglipron (AZD5004) / Eccogene, AstraZeneca
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a ...
4周减重九斤！阿斯利康披露口服小分子GLP-1药物的最新数据，超18亿美元合作有望兑现_腾讯新闻
Eccogene首次在中國進行AZD5004臨床試驗 - ss future
AZ·에코진, 경구용 GLP-1 후보 ‘AZD5004’ 中 임상1b상 돌입…첫 환자 투약
ECC5004 | GLP-1 agonist | Probechem Biochemicals
Eccogene Receives Milestone Payment of $60 Million from AstraZeneca ...
아스트라제네카 ＂비만 치료약, 초기 임상시험 결과 안전＂
ECC5004(AZD5004) GLP-1 Receptor Agonist | Selleck Chemicals
TargetMol明星分子—Orforglipron
Eccogene Announces Positive Topline Results from Phase 1b Trial of ...
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and ...
潜在重磅小分子GLP-1新药在华获批临床！阿斯利康超20亿美元合作开发
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of ...
阿斯利康：GLP-1/GCG+Amylin启动减重2b期临床
AZ, 올해 '먹는 비만약' 임상2b상 추진…"비만보다 체중관리 초점"
Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a ...
GLP-1 receptor agonist 14 | C48H46F2N10O5 | CID 167350327 - PubChem
潜在5款重磅下一代GLP-1疗法|糖尿病|阿斯利康|临床试验_新浪新闻
큐핏 - ‘비만 치료제’ 시장, 경쟁 격화…글로벌은 전략 재정비, 국내는 개발 가속화 - 2028년 전 세계 비만약 시장 480 ...
